TNFRSF9 and systemic lupus erythematosus: Although agonistic anti-CD137 antibody demonstrates alleviation of lupus in animal models [90, 91], its potential to cause atherosclerosis may be a relevant concern if this monoclonal antibody is to be evaluated in clinical trials for the treatment of SLE.